Sale of Obesity Drug Banned in India

by Kathy Jones on  November 23, 2010 at 9:45 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

The sale of anti-obesity medicine Sibutramine has been banned in India due to rising instances of heart attacks among its users, the Drugs Controller General of India (DCGI) revealed.
 Sale of Obesity Drug Banned in India
Sale of Obesity Drug Banned in India

The drug has already been banned in a number of western countries back in October this year including its combination drugs such as R-Sibutramine. The drug's manufacturer, US-based Abbott Laboratories has already stopped manufacturing and marketing of the drug, the DCGI added.

A number of recent studies, including the sibutramine cardiovascular outcomes study (SCOUT), revealed that continuous use of Sibutramine increased the risk of cardiovascular diseases including heart attacks and strokes among its users.

Following the suspension of the drug in other countries, a separate committee was constituted to look into the matter and the DCGI was advised to suspend import and manufacturing of the drug on November 12.


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Bariatric Surgery Drug Toxicity Obesity Diabetes - Essentials Binge Eating : The Pleasure and Pain Bulimia Nervosa Body Mass Index Signature Drug Toxicity Liposuction Battle of the Bulge 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive